Top 10 Challenges in Cancer Immunotherapy.
Explore this paper's citation graph
Summary
Ten key challenges facing cancer immunotherapy are defined, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient.
- Type
- review
- Published
- 2020-01-01
- Cited by
- 1,816
- References
- 189
- Access
- Open access
- OpenAlex
- https://openalex.org/W3000339487
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:210334886
Keywords
Immunotherapy, Cancer immunotherapy, Cancer, Cancer treatment, Clinical trial
References
- Natural history of HLA expression during tumour development.
- PD-1 and its ligands are important immune checkpoints in cancer
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- Translational value of mouse models in oncology drug development
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Comprehensive genomic profiles of small cell lung cancer
- Immune tolerance: what is unique about the liver.
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
- Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
- Oncology meets immunology: the cancer-immunity cycle.
- Statistical issues and challenges in immuno-oncology
- I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
- TCR repertoires of intratumoral T‐cell subsets
- Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct
Cited by
- Improved cancer immunotherapy strategies by nanomedicine.
- Engineering interferons for cancer immunotherapy.
- INTERACTIONS
- Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli—an Industry Perspective
- Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
- HSP70 Multi-Functionality in Cancer
- Pan-cancer analysis identified inflamed microenvironment associated multi-omics signatures
- Integrating the immune microenvironment of prostate cancer induced bone disease
- Molekulare zielgerichtete Therapie und Immuntherapie des Prostatakarzinoms
- Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
- In Situ Synthesis of an Aptamer-Based Polyvalent Antibody Mimic on the Cell Surface for Enhanced Interactions between Immune and Cancer Cells.
- Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy
- Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications
- Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo
- Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review
- Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis
- Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications
- Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
- New insights into the interaction of the immune system with non-small cell lung carcinomas
- PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?
Related papers
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- B7-H3/CD276: An Emerging Cancer Immunotherapy
- pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy
- Cancer Physical Hallmarks as New Targets for Improved Immunotherapy.
- The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
- Nanotechnology in the arena of cancer immunotherapy
- Drug Delivery Strategies Based on Nanotechnology for Cancer Immunotherapy
- Nanotechnology Approaches to Improving Cancer Immunotherapy